Roche Farma
Roche Farma is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging
Sponsor Asociacion Instituto De Investigacion Sanitaria Biobizkaia
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positive advanced/metastatic breast cancer – ATREZZO Study
Sponsor Solti Group
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and bevacizumab as neoadjuvant plus adjuvant treatment in hepatocellular carcinoma (ASPIRE)
Sponsor Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS
Sponsor Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Roche Farma?
The 2026-10-09 snapshot links Roche Farma to 4 distinct CTIS trials. Recorded services include Distribution and Management of PR1, Site of Certification and Importation for Avastin and Tecentriq, Site of certification and importation for Vabysmo, Site of Certification for Products Trastuzumab and Pertuzumab. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Roche Farma?
The most frequently recorded therapeutic areas are Ophthalmology. Recorded phases include Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Roche Farma conducted?
The linked trials record locations in 3 countries, including Spain, Germany, Italy. These are trial locations, not confirmed office locations or countries where Roche Farma delivered services.
What can this page tell me about Roche Farma's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Roche Farma. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Roche Farma S.A.